Abstract: The Applicant has discovered that the peptide of SEQUENCE ID NO: 1 (WKDEAGKPLVK) mediates changes in key biomarker activities associated with NASH (Table 1), and that the peptide is capable of penetrating HepG2 liver cells in a hepatic cell penetration assay (FIG. 1). In addition, the Applicant demonstrates that treatment with pep_260 (SEQ ID 1) for 44 days significantly relieves macro-vesicular steatosis in obese diabetic KKAy mice (FIG. 2) In a first aspect, the invention relates to the use of a peptide comprising SEQUENCE ID NO: 1, or a functional (or therapeutically effective) variant or functional fragment of SEQUENCE ID NO: 1 (hereafter “peptide active agent” or “peptide of the invention”), in a method for the treatment or prevention of non-alcoholic fatty liver disease (NAFLD), in particular non-alcoholic steatohepatitis (NASH), in a mammal.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NO’s: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NO’s: 15 to 505, and 546 to 704.

Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQ ID NOs: 1-16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C) The anti-inflammatory fragment is from a region of the proteins of SEQ ID NOs: 1-16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQ ID NOs: 71-221.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NOs: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NOs: 15 to 505, and 546 to 704.

Abstract: The inventors have discovered that the peptide of SEQUENCE ID NO: 1 (WKDEAGKPLVK) targets PANX1. The invention also concerns treatment of diseases associated with PANX1 with the peptide or a composition comprising the peptide.

Abstract: The Applicant has discovered a number of peptides that are capable of phosphorylating ribosomal protein S6 (rpS6) across a range of concentrations in in-vitro cell assays in a dose-dependent manner. RPS6 is a key substrate for protein kinases and is phosphorylated by growth factors and mitogens during in cell growth and cell division. This is a key step in the synthesis of new proteins in skeletal muscle tissue. The peptides described also have the ability to reduce the expression of mRNA Transcripts (TRIM63 and FBXO32) that are directly linked to increase protein degradation, resulting in progressive Skeletal Muscle Atrophy. In addition, increases in muscular atrophy are linked with systemic rise in circulating TNF?. The peptides described herein also lead to the reduced expression of TNF? in circulating immune cells.

Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQUENCE ID NO's: 1 to 16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C). The anti-inflammatory fragment is from a region of the proteins of SEQUENCE ID NO's: 1 to 16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQUENCE ID NO's: 71 to 221.

Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQ ID NOs: 1 to 16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C). The anti-inflammatory fragment is from a region of the proteins of SEQ ID NOs: 1 to 16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQ ID NOs: 71 to 221.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NOs: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NOs: 15 to 505, and 546 to 704.

Abstract: A natural glucose transport promoting peptide comprising a glucose transport promoting fragment of a protein selected from SEQ ID NOs: 1 to 6, and a composition comprising a plurality of glucose transport promoting peptides, is described. Also disclosed is the use of the peptides and compositions in improving muscle status in a mammal, especially promoting recovery of muscle following exercise or enhancing physical performance.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NOs: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NOs: 15 to 505, and 546 to 704.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQUENCE ID NO'S 15 to 505, and 546 to 704.

Abstract: A composition comprising a cosmetically or pharmaceutically or therapeutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO. 1. Modified peptides, and therapeutic and cosmetic uses of the peptide are also disclosed.

Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQUENCE ID NO's: 1 to 16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C). The anti-inflammatory fragment is from a region of the proteins of SEQUENCE ID NO's: 1 to 16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQUENCE ID NO's: 71 to 221.

Abstract: A composition comprising a cosmetically or pharmaceutically or therapeutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO. 1. Modified peptides, and therapeutic and cosmetic uses of the peptide are also disclosed.

Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQUENCE ID NO's: 1 to 16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C). The anti-inflammatory fragment is from a region of the proteins of SEQUENCE ID NO's: 1 to 16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQUENCE ID NO's: 71 to 221.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NO's: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NO's: 15 to 505, and 546 to 704.

Abstract: A composition comprising a plurality of bioactive peptides including SEQUENCE ID NO's 555 and 701 is described. The composition may be a powder that is enriched in peptides having a molecular weight less than 10 KD. The bioactive peptides included in the composition have been found to have anti-inflammatory, glucose-transport promoting, and cellular growth promoting activities.

Abstract: A natural glucose transport promoting peptide comprising a glucose transport promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 6, and a composition comprising a plurality of glucose transport promoting peptides, is described. Also disclosed is the use of the peptides and compositions in improving muscle status in a mammal, especially promoting recovery of muscle following exercise or enhancing physical performance.

Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQUENCE ID NO'S 15 to 505, and 546 to 704.